vTv Therapeutics Inc-A 2025年季度报告

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 (Mark One) For the quarterly period endedSeptember 30, 2025Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission file number:001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) (336)841-0300(Registrant’s telephone number, including area code)(Former name, former address and former fiscal year, if changed since last report)_____________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Class of Stock Class A common stock, par value $0.01 per shareClass B common stock, par value $0.01 per share vTv THERAPEUTICS INC. AND SUBSIDIARIESINDEX TO FORM 10-QFOR THE QUARTER ENDED SEPTEMBER30, 2025 PART I – FINANCIAL INFORMATIONItem 1.Condensed Consolidated Balance Sheets as ofSeptember30, 2025 (Unaudited) and December 31, 20244Unaudited Condensed Consolidated Statements of Operations for the three andninemonths endedSeptember30, 2025 and 20245Unaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest andStockholders’ Equity (Deficit) for the three andninemonths endedSeptember30, 2025 and 20246Unaudited Condensed Consolidated Statements of Cash Flows for theninemonths endedSeptember30,2025 and 20248Notes to Unaudited Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29PART II – OTHER INFORMATIONItem 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity Securities and Use of Proceeds30Item 3.Defaults Upon Senior Securities30Item 4.Mine Safety Disclosures30Item 5.Other Information30Item 6.Exhibits31Signatures32 PART I – FINANCIAL INFORMATION The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the“Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principaloperating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the“Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries. vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands, except number of shares and per share data) vTv Therapeutics Inc. Condensed Consolidated Statements of Operations - Unaudited (in thousands, except number of shares and per share data) vTv Therapeutics Inc. (in thousands, except number of shares)For the three months ended September 30, 2025 (in thousands, except number of shares) vTv Therapeutics Inc. Condensed Consolidated Statements of Cash Flows - Unaudited (in thousands) vTv Therapeutics Inc.Notes to Condensed Consolidated Financial Statements – Unaudited(dollar amounts are in thousands, unless otherwise noted) Note 1:Description of Business and Basis of Presentation Description of Business vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015.The Company is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended tohelp treat people living with diabetes and other chronic diseases. The Company’s clinical pipeline is led bycadisegliatin, currently in aPhase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulinfor the treatment of type 1 diabetes. The Company and its development partners are